SICHUAN BIOKIN PHARMACEUTICAL C

SICHUAN BIOKIN PHARMACEUTICAL C — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2014Dec 31, 2014	FY 2013Dec 31, 2013	FY 2012Dec 31, 2012	FY 2011Dec 31, 2011
+Revenue	5.8B	562.0M	703.0M	797.0M	1.0B	1.2B	1.1B	418.0M	415.0M	387.0M	366.0M
Revenue Growth %	936.1%	-20.1%	-11.8%	-21.3%	-16.1%	8.6%	165.8%	0.7%	7.2%	5.7%	--
Total Revenue	5.8B	562.0M	703.0M	797.0M	1.0B	1.2B	1.1B	418.0M	415.0M	387.0M	366.0M
Cost Of Revenue	264.0M	229.0M	233.0M	198.0M	201.0M	230.0M	234.0M	149.0M	145.0M	146.0M	134.0M
+Gross Profit	5.6B	333.0M	470.0M	599.0M	812.0M	977.0M	877.0M	269.0M	270.0M	241.0M	232.0M
Gross Margin %	95.5%	59.3%	66.9%	75.2%	80.2%	80.9%	78.9%	64.4%	65.1%	62.3%	63.4%
Total Operating Cost	1.9B	1.4B	1.1B	969.0M	1.1B	1.3B	1.1B	400.0M	380.0M	341.0M	323.0M
Selling Expenses	215.0M	251.0M	324.0M	391.0M	576.0M	772.0M	650.0M	129.0M	129.0M	119.0M	125.0M
Admin Expenses	190.0M	117.0M	78.7M	76.2M	60.4M	59.1M	50.9M	95.2M	84.2M	58.9M	51.3M
Rd Expenses	1.4B	746.0M	375.0M	279.0M	196.0M	181.0M	144.0M	--	--	--	--
Finance Expenses	-226.0M	20.8M	22.0M	8.7M	5.3M	3.1M	-1.2M	19.6M	15.8M	11.4M	9.0M
+Operating Income	4.0B	-769.0M	-288.0M	-101.0M	46.7M	11.8M	31.6M	18.9M	35.1M	47.3M	40.3M
Operating Margin %	68.3%	-136.8%	-41.0%	-12.7%	4.6%	1.0%	2.8%	4.5%	8.5%	12.2%	11.0%
Non Operating Income	1.5M	2.3M	64,600	151,200	730,400	1.3M	11.5M	9.6M	9.3M	6.9M	10.8M
Non Operating Expenses	2.3M	1.9M	1.5M	3.1M	1.8M	813,600	846,500	4.9M	2.0M	667,600	909,600
Investment Income	19.2M	3,899	--	3.1M	2.5M	161,300	139,600	34,200	40,200	38,400	62,200
Fair Value Change Income	11.4M	--	--	--	340,200	--	--	616,500	516,000	1.3M	-3.0M
Asset Disposal Income	-400.00	146,400	-19,400	9,300	--	--	--	--	--	--	--
Asset Impairment Loss	19.4M	13.0M	5.0M	5.7M	1.1M	4.1M	11.4M	2.0M	1.1M	461,400	-1.1M
Other Income	44.7M	49.8M	68.2M	67.9M	85.2M	70.8M	28.9M	--	--	--	--
Income Before Tax	4.0B	-769.0M	-289.0M	-104.0M	45.6M	12.3M	42.2M	23.6M	42.3M	53.5M	50.2M
Income Tax	271.0M	11.5M	-6.7M	-4.4M	7.7M	4.6M	9.4M	6.2M	7.5M	7.3M	10.3M
+Net Income	3.7B	-780.0M	-282.0M	-100.0M	37.9M	7.7M	32.8M	17.5M	34.8M	46.2M	39.9M
Net Margin %	63.7%	-138.8%	-40.1%	-12.5%	3.7%	0.6%	3.0%	4.2%	8.4%	11.9%	10.9%
Net Income Attributable	3.7B	-780.0M	-282.0M	-100.0M	37.9M	7.7M	32.8M	17.5M	34.8M	46.2M	39.9M
Minority Interest	--	--	--	--	21,300	11,400	1,600	--	--	--	--
Eps Basic	9.25	-1.95	-0.78	-0.28	0.11	0.02	0.09	0.17	0.33	0.44	0.73
Eps Diluted	9.25	-1.95	-0.78	-0.28	0.11	0.02	0.09	0.17	0.33	0.44	0.73

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2014Dec 31, 2014	FY 2013Dec 31, 2013	FY 2012Dec 31, 2012	FY 2011Dec 31, 2011
Cash And Equivalents	3.2B	404.0M	1.0B	154.0M	45.2M	244.0M	231.0M	63.4M	40.1M	60.9M	52.2M
Trading Financial Assets	--	--	--	--	198.0M	--	--	6.5M	5.9M	5.6M	4.3M
Accounts Receivable	107.0M	98.4M	229.0M	105.0M	163.0M	207.0M	265.0M	58.5M	50.0M	43.9M	41.9M
Notes Receivable	11.9M	19.7M	18.8M	22.9M	34.8M	52.6M	79.6M	42.3M	48.3M	41.6M	34.5M
Notes And Accounts Receivable	119.0M	118.0M	247.0M	128.0M	198.0M	260.0M	344.0M	101.0M	98.3M	85.5M	76.5M
Prepayments	81.6M	57.2M	29.8M	22.9M	13.2M	10.4M	12.9M	12.5M	9.3M	5.6M	11.8M
Inventory	162.0M	141.0M	101.0M	82.3M	65.8M	77.3M	72.2M	52.7M	34.3M	39.3M	41.1M
Total Current Assets	6.3B	776.0M	1.4B	424.0M	571.0M	659.0M	687.0M	240.0M	197.0M	202.0M	191.0M
Long Term Equity Investment	--	--	--	--	--	--	--	--	--	--	50,000
Fixed Assets	--	448.0M	341.0M	373.0M	304.0M	327.0M	323.0M	281.0M	207.0M	172.0M	90.6M
Fixed Assets Total	499.0M	448.0M	341.0M	373.0M	304.0M	327.0M	323.0M	281.0M	207.0M	172.0M	90.6M
Construction In Progress	--	81.4M	67.2M	18.2M	76.7M	21.3M	3.6M	5.0M	55.5M	41.2M	65.9M
Construction In Progress Total	35.5M	81.4M	67.2M	18.2M	76.7M	21.3M	3.6M	5.0M	55.5M	41.2M	65.9M
Intangible Assets	26.7M	28.0M	29.5M	31.2M	32.9M	34.5M	36.0M	34.5M	31.6M	34.2M	36.3M
Long Term Deferred Expenses	18.4M	1.8M	1.8M	1.2M	671,800	941,200	354,300	--	--	--	--
Total Non Current Assets	830.0M	649.0M	565.0M	528.0M	471.0M	432.0M	406.0M	433.0M	425.0M	349.0M	276.0M
Total Assets	7.1B	1.4B	2.0B	951.0M	1.0B	1.1B	1.1B	673.0M	621.0M	551.0M	467.0M
Short Term Borrowings	596.0M	275.0M	155.0M	161.0M	150.0M	195.0M	142.0M	189.0M	142.0M	176.0M	137.0M
Accounts Payable	393.0M	308.0M	185.0M	72.6M	68.0M	56.6M	61.1M	39.8M	35.9M	32.8M	24.8M
Advance Receipts	--	--	--	--	--	26.1M	21.2M	6.6M	8.6M	4.9M	10.0M
Contract Liabilities	356.0M	8.7M	17.4M	10.8M	18.1M	--	--	--	--	--	--
Total Current Liabilities	2.0B	1.1B	737.0M	471.0M	532.0M	614.0M	619.0M	380.0M	289.0M	295.0M	242.0M
Long Term Borrowings	1.2B	184.0M	240.0M	50.0M	--	--	--	15.0M	65.0M	20.5M	35.5M
Total Non Current Liabilities	1.3B	219.0M	320.0M	148.0M	57.5M	48.3M	35.8M	18.9M	68.5M	22.0M	36.8M
Total Liabilities	3.3B	1.3B	1.1B	620.0M	590.0M	662.0M	655.0M	399.0M	358.0M	317.0M	278.0M
Paid In Capital	401.0M	401.0M	401.0M	361.0M	361.0M	116.0M	116.0M	105.0M	105.0M	105.0M	105.0M
Capital Reserve	886.0M	859.0M	859.0M	14.2M	14.1M	253.0M	253.0M	--	--	--	--
Surplus Reserve	13.5M	13.5M	13.5M	13.5M	13.5M	10.6M	10.6M	3.3M	697,500	697,500	--
Retained Earnings	2.6B	-1.1B	-342.0M	-59.5M	60.5M	33.5M	43.7M	165.0M	158.0M	128.0M	83.8M
Minority Equity	--	--	--	--	--	10.0M	10.0M	--	--	--	--
Equity Attributable	3.9B	152.0M	934.0M	332.0M	452.0M	418.0M	428.0M	274.0M	264.0M	234.0M	189.0M
Total Equity	3.9B	152.0M	934.0M	332.0M	452.0M	428.0M	438.0M	274.0M	264.0M	234.0M	189.0M

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2014Dec 31, 2014	FY 2013Dec 31, 2013	FY 2012Dec 31, 2012	FY 2011Dec 31, 2011
Cash From Sales	6.1B	586.0M	516.0M	844.0M	1.1B	1.3B	1.1B	313.0M	307.0M	294.0M	276.0M
Tax Refunds Received	4.1M	29.0M	33.6M	13.0M	19.4M	24.5M	21.4M	6.2M	7.2M	6.0M	6.4M
Total Operating Cash Inflow	6.4B	707.0M	614.0M	921.0M	1.2B	1.4B	1.2B	328.0M	327.0M	312.0M	297.0M
Cash Paid For Goods	89.1M	64.0M	56.0M	119.0M	129.0M	128.0M	115.0M	53.5M	33.5M	25.9M	24.2M
Cash Paid To Employees	513.0M	306.0M	241.0M	200.0M	185.0M	206.0M	177.0M	85.6M	72.2M	62.5M	63.6M
Taxes Paid	432.0M	78.0M	70.2M	114.0M	147.0M	173.0M	176.0M	50.5M	67.0M	69.3M	44.3M
Total Operating Cash Outflow	2.3B	1.3B	872.0M	1.1B	1.1B	1.4B	1.1B	315.0M	300.0M	269.0M	230.0M
Operating Cash Flow	4.1B	-615.0M	-259.0M	-135.0M	78.5M	28.0M	69.5M	13.2M	26.3M	43.2M	67.2M
Total Investing Cash Inflow	1.9B	20.1M	10,300	480.0M	240.0M	45.2M	5.1M	34,200	411,500	38,400	662,200
Total Investing Cash Outflow	4.4B	102.0M	34.6M	324.0M	450.0M	66.0M	36.9M	24.0M	47.6M	59.9M	116.0M
Investing Cash Flow	-2.6B	-81.9M	-34.5M	156.0M	-210.0M	-20.8M	-31.8M	-24.0M	-47.2M	-59.8M	-115.0M
Cash From Borrowings	1.9B	448.0M	375.0M	242.0M	150.0M	195.0M	169.0M	261.0M	202.0M	233.0M	137.0M
Dividends And Interest Paid	38.4M	18.8M	12.6M	27.0M	10.0M	30.1M	21.6M	26.7M	20.2M	12.6M	8.7M
Debt Repayments	519.0M	240.0M	161.0M	181.0M	195.0M	153.0M	279.0M	184.0M	196.0M	203.0M	125.0M
Total Financing Cash Inflow	1.9B	448.0M	1.4B	302.0M	150.0M	200.0M	169.0M	283.0M	228.0M	250.0M	251.0M
Total Financing Cash Outflow	630.0M	357.0M	236.0M	213.0M	215.0M	185.0M	314.0M	273.0M	234.0M	224.0M	183.0M
Financing Cash Flow	1.3B	90.8M	1.1B	88.7M	-64.8M	14.6M	-145.0M	9.9M	-5.7M	25.7M	68.0M
Net Change In Cash	2.8B	-609.0M	846.0M	109.0M	-198.0M	24.0M	-93.3M	-947,600	-26.5M	9.1M	20.1M
Ending Cash Balance	3.2B	392.0M	1.0B	154.0M	45.2M	244.0M	220.0M	33.4M	34.4M	60.9M	51.7M
Capex	83.9M	81.9M	34.6M	44.6M	15.4M	21.0M	30.9M	24.0M	47.6M	59.9M	81.7M